Market Opportunity

Everyone serves the 12%
We serve the 88%

Arcus Medical targets the vast underserved population of women seeking minimally invasive pelvic organ prolapse care.

The Untreated Majority

A massive population suffering in silence

Women undergoing surgery 12%

~800K women choose invasive surgical repair

Women left untreated 88%

~5.8M women avoid surgery due to cost, recovery time, and stigma

5.8 Million

U.S. women are actively seeking minimally invasive, office-based alternatives

Market Sizing

From global prevalence to addressable opportunity

150M

Total Addressable Market

Women globally affected by pelvic organ prolapse.

6.6M

Serviceable Addressable Market

U.S. women diagnosed with symptomatic POP.

5.8M

Serviceable Obtainable Market

Untreated women seeking non-surgical alternatives.

$900M

Annual U.S. Market Opportunity

Sizable multi-hundred million dollar opportunity in untreated segment alone.

Key Market Drivers

Why the timing is perfect for Arcus TLT

↗

Aging Population

POP prevalence increases with age. Baby boomers represent a massive and growing patient population seeking quality of life improvements.

↗

FDA Mesh Removal

FDA order to stop sale of transvaginal synthetic mesh created a massive vacuum with no direct replacement solution available.

↗

Shift to Office-Based Care

Healthcare cost pressures drive procedures to lower-cost settings while maintaining quality outcomes.

↗

Patient Preference for Minimally Invasive

Growing demand for minimally invasive alternatives with faster recovery times and lower risk profiles.

↗

Reduced Stigma & Awareness

Increasing public awareness and reduced stigma around women's pelvic health issues leads to more women seeking treatment.

Competitive Landscape

Arcus advantage: targeting the underserved 88%

Traditional Market (12%)

Where everyone else competes

Surgical mesh manufacturers (pre-FDA ban) Traditional surgical instrument companies Hospital-based procedures only Pessary device manufacturers Highly saturated, competitive market

Arcus TLT Market (88%)

Where we dominate

5.8M untreated women seeking alternatives Office/ASC-based lower cost setting Minimal competition in this segment Post-mesh ban opportunity First-mover advantage in underserved market

Significant TLT Advantage

While competitors fight over the saturated 12% surgical market, Arcus Medical owns the massive 88% non-surgical segment with minimal direct competition.

7x

Larger addressable market

1st

First office-based solution

$900M

Untapped opportunity

Current Market Limitations

3,000 years of limited progress in treating POP

Vaginal Pessaries

The oldest documented treatment, yet still widely used today:

Uncomfortable and require frequent maintenance Low patient compliance and satisfaction Outdated solution that doesn't address root cause Many women simply give up on treatment

Traditional Surgery

Invasive procedures with significant barriers:

Requires hospital setting and general anesthesia High cost and extended recovery time FDA removed transvaginal mesh creating vacuum Only 12% of affected women choose this option

The Market Need

A simple, office-based, minimally invasive solution with immediate reimbursement — exactly what Arcus TLT provides.

Partner With Us

Ready to review the Arcus Medical opportunity?

Access investor materials or schedule a discussion with the Arcus team.

Schedule a Meeting Request Materials